We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 2.09% | 7.34 | 7.32 | 7.34 | 7.63 | 7.19 | 7.41 | 2,019,130 | 00:45:33 |
Scot Roberts, Ph.D., Chief Scientific Officer at Altimmune and Dr. Sarah K. Browne, Senior Director, Vaccine Development at Altimmune will give an oral presentation highlighting the Company’s AdCOVID™ intranasal COVID-19 vaccine candidate at the World Vaccine Congress, taking place May 4-7, 2021.
Dr. Scott Harris, Chief Medical Officer at Altimmune will give an oral presentation at the Chronic Hepatitis B Drug Development Virtual Summit, taking place May 5-6, 2021, during which he will provide an overview of HepTcell™, a novel peptide-based immunotherapeutic being developed by Altimmune for the treatment of chronic hepatitis B (CHB).
Details on the World Vaccine Congress presentation are as follows:
Title: | AdCOVID – A Single-Dose Intranasal Vaccine for COVID-19 |
Presenters: | Scot Roberts, Ph.D., Chief Scientific Officer at AltimmuneDr. Sarah K. Browne, Senior Director, Vaccine Development at Altimmune |
Date: | May 4, 2021 (virtual pre-record available) |
Details on the Chronic Hepatitis B Drug Development Virtual Summit presentation are as follows:
Title: | How We Can Achieve Success with Immunotherapeutics in the Treatment of Chronic Hepatitis B |
Presenter: | Scott Harris M.D., Chief Medical Officer at Altimmune. Inc. |
Date/Time: | May 5, 2021 at 1:30 pm ET |
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Altimmune Investor & Media Contacts:
Will Brown | Stacey Jurchison |
Chief Financial Officer | Sr. Dir, Investor Relations |
Phone: 240-654-1450 | Phone : 410-474-8200 |
wbrown@altimmune.com | sjurchison@altimmune.com |
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions